Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats
Daniel I. Brierley, James Samuels, Marnie Duncan, et al.
Psychopharmacology (2016) Vol. 233, Iss. 19-20, pp. 3603-3613
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Secondary Metabolites Profiled in Cannabis Inflorescences, Leaves, Stem Barks, and Roots for Medicinal Purposes
Dan Jin, Kaiping Dai, Zhen Xie, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 258
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Eric P. Baron
Headache The Journal of Head and Face Pain (2018) Vol. 58, Iss. 7, pp. 1139-1186
Closed Access | Times Cited: 212
The Pharmacological Case for Cannabigerol
Rahul Nachnani, Wesley M. Raup‐Konsavage, Kent E. Vrana
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 376, Iss. 2, pp. 204-212
Open Access | Times Cited: 149
Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses
Zeinab Breijyeh, Buthaina Jubeh, Sabino Aurelio Bufo, et al.
Toxins (2021) Vol. 13, Iss. 2, pp. 117-117
Open Access | Times Cited: 84
Constituents of Cannabis Sativa
Erin M. Rock, Linda A. Parker
Advances in experimental medicine and biology (2020), pp. 1-13
Closed Access | Times Cited: 79
Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors
Gemma Navarro, Katia Varani, Alejandro Lillo, et al.
Pharmacological Research (2020) Vol. 159, pp. 104940-104940
Open Access | Times Cited: 76
Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol
Patrycja Bielawiec, Ewa Harasim‐Symbor, Adrian Chabowski
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 75
The Medicinal Natural Products of Cannabis sativa Linn.: A Review
Anwuli Endurance Odieka, Gloria Ukalina Obuzor, Opeoluwa O. Oyedeji, et al.
Molecules (2022) Vol. 27, Iss. 5, pp. 1689-1689
Open Access | Times Cited: 65
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
Fabrizio Calapai, Luigi Cardia, Emanuela Esposito, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-14
Open Access | Times Cited: 42
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
Leontina Elena Filipiuc, Daniela Carmen Ababei, Teodora Alexa‐Stratulat, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1823-1823
Open Access | Times Cited: 54
Phytocannabinoid Pharmacology: Medicinal Properties of Cannabis sativa Constituents Aside from the “Big Two”
Peter B. Sampson
Journal of Natural Products (2020) Vol. 84, Iss. 1, pp. 142-160
Closed Access | Times Cited: 50
Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol
Daniel I. Brierley, Joe Harman, Natasa Giallourou, et al.
Journal of Cachexia Sarcopenia and Muscle (2019) Vol. 10, Iss. 4, pp. 844-859
Open Access | Times Cited: 45
Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids
Rafael Franco, Rafael Rivas‐Santisteban, Irene Reyes‐Resina, et al.
Pharmacological Research (2020) Vol. 158, pp. 104801-104801
Closed Access | Times Cited: 40
Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus
Viviana di Giacomo, Annalisa Chiavaroli, Giustino Orlando, et al.
Antioxidants (2020) Vol. 9, Iss. 1, pp. 71-71
Open Access | Times Cited: 39
Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms
Ethan B. Russo, Carrie Cuttler, Ziva D. Cooper, et al.
Cannabis and Cannabinoid Research (2021) Vol. 7, Iss. 5, pp. 706-716
Closed Access | Times Cited: 37
Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots
Dan Jin, Philippe Henry, Jacqueline J. Shan, et al.
Frontiers in Plant Science (2021) Vol. 12
Open Access | Times Cited: 34
Comprehensive mini-review: therapeutic potential of cannabigerol – focus on the cardiovascular system
Anna Krzyżewska, Monika Kloza, Hanna Kozłowska
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The Identification of Novel Anti-Inflammatory Effects of Cannabigerol in the Kidney Tissue of Rats Subjected to a High-Fat High-Sucrose Diet
Anna Stepaniuk, Klaudia Sztolsztener, Karolina Konstantynowicz-Nowicka, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3114-3114
Open Access
Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi
Muna Aqawi, Ruth Gallily, Ronit Vogt Sionov, et al.
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 32
Antimicrobial and Cytotoxic Effects of Cannabinoids: An Updated Review with Future Perspectives and Current Challenges
Mansab Ali Saleemi, Noorfatimah Yahaya, Nur Nadhirah Mohamad Zain, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 10, pp. 1228-1228
Open Access | Times Cited: 19
Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer’s Disease
Sumit Rathod, Yogeeta O. Agrawal
Current Drug Research Reviews (2023) Vol. 16, Iss. 2, pp. 94-110
Closed Access | Times Cited: 11
In the weeds: A comprehensive review of cannabis; its chemical complexity, biosynthesis, and healing abilities
Fatima-Zahrae Laaboudi, Mohamed Rejdali, Hassan Amhamdi, et al.
Toxicology Reports (2024) Vol. 13, pp. 101685-101685
Open Access | Times Cited: 4
Cannabinoids-Promising Antimicrobial Drugs or Intoxicants with Benefits?
Philipp Klahn
Antibiotics (2020) Vol. 9, Iss. 6, pp. 297-297
Open Access | Times Cited: 31
Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain
Catherine F. Moore, Elise M. Weerts, Justyna Kulpa, et al.
Cannabis and Cannabinoid Research (2023) Vol. 8, Iss. S1, pp. S51-S61
Closed Access | Times Cited: 10
Cannabigerol and cannabichromene in Cannabis sativa L.
Marjeta Zagožen, A. Čerenak, Samo Kreft
Acta Pharmaceutica (2020) Vol. 71, Iss. 3, pp. 355-364
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top